Latest Strategic Pivot News

Genetic Signatures Ltd reported a robust 71% jump in quarterly sales to $2.9 million, fueled by strong respiratory testing demand in Australia and key US commercial contracts. The company is advancing its automation and instrument customisation strategy to streamline molecular diagnostics offerings.

Equity Story Group Ltd reported a robust 56% revenue increase in the March 2025 quarter, driven by strong fund performance and membership growth, alongside a strategic investment and plans to acquire Baker Young Limited.

Arizona Lithium advances its Prairie Project with a pioneering commercial development plan for lithium brine extraction, regulatory approvals, and a $1.3 million capital raise to fund initial production.

Atomos Limited reported a $2.3 million operating cash outflow in Q3 FY25 amid seasonal softness and tariff challenges, while announcing a leadership change and a bold expansion into new product categories beyond its core monitor-recorder business.

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Zoom2u Technologies reports steady group revenue with Locate2u growing 10%, supported by AI initiatives that cut staff costs and a $0.5 million capital raise.

Global Lithium Resources has resumed its Definitive Feasibility Study at the Manna Lithium Project, focusing on cost optimization and project economics, while advancing heritage and native title agreements. The company also reported significant board changes and a robust cash position heading into 2025.

Petratherm Limited has confirmed a significant titanium-rich heavy mineral sands discovery at its Muckanippie Project, with drilling extending mineralisation over 15 square kilometres and a recent $8.1 million placement to accelerate development.

AnteoTech Ltd reports progress in advanced battery and life sciences technologies alongside a strategic review and leadership changes amid challenging EV market conditions.

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Fluence Corporation Limited reported a robust 64.5% revenue increase in Q1 2025, driven by a strategic pivot to higher-margin Smart Product Solutions and recurring revenue streams, while maintaining its full-year guidance.

Cosmo Metals has completed the acquisition of the Bingara and Nundle gold-antimony-copper projects in NSW and progressed exploration at its Kanowna Gold Project in WA, supported by a $1.1 million capital raise.